광동제약

009290KOSPI의약품 제조업

52.5 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment19.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 22.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Guangdong Pharmaceutical operates through three divisions—OTC, ETC, and F&B—selling products like Cheongshimwon, Jeju Samdaewon, and Gardasil, with 98.6% of sales coming from the domestic market. In 2025, the company achieved sales of 10.11 trillion KRW and aims to expand into natural product markets, digital innovation, and healthcare platforms to become a 'Human Healthcare Brand' enterprise.

Number of Employees

1,022people

Average Salary

78.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.98Industry Average 11.933.0Point

Higher than industry avg (caution)

PBR

0.44Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE

3.21Industry Average 4.012.5Point

Below industry avg

Debt Ratio

11.61Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼12.7% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 5.7% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 11Neutral 3Negative 0Average Sentiment Score 76.1

Positive
‘내부 감시망’ 전면배치한 광동제약… 부패방지위원회 격상해 통제...
광동제약이 내부 감시 체계를 강화하여 부패 방지를 위한 조직 개편과 ISO 인증 기반 모니터링 체계 구축으로 신뢰성과 윤리 준수를 향상시켰다.
Positive
광동제약, ‘윤리데이’ 제정... 윤리경영 시스템 고도화
광동제약이 윤리경영 강화를 위한 '윤리데이' 도입과 컴플라이언스 조직 확대를 통해 기업 윤리 수준 향상 기대.
Positive
광동제약, '윤리데이' 제정…"내부감시 강화" 컴플라이언스위원회 출....
광동제약이 윤리데이 도입과 컴플라이언스 위원회 강화를 통해 준법경영 체계를 개선함으로써 기업의 윤리적 신뢰성과 투명성이 높아질 것으로 기대된다.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 6,240Won52-week high 11,08052-week low 5,600

1-month return0.0Point

1m -22.10% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-05-29
Neutral분기보고서 (2026.03)2026-05-15